Tol, J <br/><br/>
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Apr 2008 
 - 734-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdm607  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>Capecitabine<br/>Carcinoma--drug therapy<br/>Cetuximab<br/>Colorectal Neoplasms--drug therapy<br/>Deoxycytidine--administration & dosage<br/>Disease-Free Survival<br/>Drug Eruptions--etiology<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Incidence<br/>Male<br/>Middle Aged<br/>Netherlands<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Severity of Illness Index<br/>Survival Analysis<br/>Treatment Outcome